Harvest Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Harvest Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-694	Closed	-$76K	–	800
2023 Q1	$76K	Hold	694	–	–	0.02%	399
2022 Q4	$79K	Buy	+694	New	+$57.6K	0.02%	391
2022 Q3	–	Sell	-1,561	Closed	-$125K	–	852
2022 Q2	$125K	Hold	1,561	–	–	0.03%	259
2022 Q1	$164K	Hold	1,561	–	–	0.03%	258
2021 Q4	$168K	Buy	1,561 +243	+18%	+$26.5K	0.03%	270
2021 Q3	$144K	Sell	1,318 -35	-3%	-$3.63K	0.03%	219
2021 Q2	$130K	Hold	1,353	–	–	0.01%	219
2021 Q1	$124K	Buy	+1,353	New	+$114K	0.01%	220
2020 Q4	–	Sell	-4,004	Closed	-$326K	–	685
2020 Q3	$326K	Buy	4,004 +1,089	+37%	+$74.9K	0.03%	110
2020 Q2	$160K	Sell	2,915 -662	-19%	-$28.3K	0.01%	174
2020 Q1	$105K	Buy	+3,577	New	+$121K	0.01%	196

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Harvest Fund Management's HZNP Position: Q2 2023 in Review

Harvest Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 694 shares — an estimated $76K sold.

Harvest Fund Management first reported a position in HZNP in Q1 2020 and held it in 11 quarters. The position peaked at $326K in Q3 2020. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Harvest Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Harvest Fund Management sold 694 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $76K.
Harvest Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 11 quarters.
Harvest Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $326K in Q3 2020.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Harvest Fund Management's 13F filing for Q2 2023, filed 7 Jul 2023.